0000899243-19-000956.txt : 20190110 0000899243-19-000956.hdr.sgml : 20190110 20190110160930 ACCESSION NUMBER: 0000899243-19-000956 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190108 FILED AS OF DATE: 20190110 DATE AS OF CHANGE: 20190110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novak Rodger CENTRAL INDEX KEY: 0001682017 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 19520353 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-08 0 0001674416 CRISPR Therapeutics AG CRSP 0001682017 Novak Rodger C/O CRISPR THERAPEUTICS AG BAARERSTRASSE 14 ZUG V8 CH-6300 V8 SWITZERLAND 1 1 0 0 President Common Shares 2019-01-08 4 S 0 17310 35.09 D 1130697 D Common Shares 2019-01-09 4 S 0 82690 35.01 D 1048007 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.105, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Michael Esposito, attorney-in-fact 2019-01-10